Common decision limits --The need for harmonised immunoassays

Area of Science:

• Clinical Chemistry
• Medical Diagnostics
• Biochemical Analysis

Background:

• Clinical guidelines are essential for standardizing patient care and resource allocation.
• Decision limits in guidelines often rely on analyte levels in biological samples (serum, plasma, urine).
• Discrepancies between different measurement methods can impact clinical decisions.

Purpose of the Study:

• To highlight the importance of addressing method-related differences in clinical guideline implementation.
• To emphasize the potential serious patient consequences arising from variations in analyte measurements.
• To review causes of between-method differences and propose solutions.

Main Methods:

• Review of existing evidence on method-related differences in analyte measurements.
• Analysis of the impact of these differences on clinical decision-making.
• Identification of major causes contributing to measurement variability.

Main Results:

• Method-related differences in analyte measurements can significantly affect patient management.
• Examples include prostate-specific antigen (PSA) testing, where variations can lead to missed or unnecessary biopsies.
• Significant implications for patient care exist if common decision limits are implemented without considering method variability.

Conclusions:

• Standardization of measurement methods is crucial for the reliable application of clinical guidelines.
• Addressing between-method differences is necessary to ensure consistent and accurate patient diagnosis and treatment.
• Further efforts are needed to minimize analytical variability and improve patient outcomes.